ARTICLE | Clinical News
Emtricitabine/tenofovir/rilpivirine regulatory update
September 6, 2010 7:00 AM UTC
Gilead submitted an MAA to EMA for a fixed-dose combination of Johnson & Johnson's rilpivirine and Gilead's Truvada emtricitabine/tenofovir to treat HIV-1 infection in adults. Gilead partnered with J...